PHBBF vs REGN: Which Stock is Better?
Side-by-side comparison of Pharmaron Beijing Co., Ltd. and Regeneron Pharmaceuticals Inc in 2026
PHBBF
Pharmaron Beijing Co., Ltd.
$1.93
REGN
Regeneron Pharmaceuticals Inc
$750.57
Key Metrics Comparison
| Metric | PHBBF | REGN | Winner |
|---|---|---|---|
| Market Cap | $3.55B | $79.35B | REGN |
| P/E Ratio | 16.08 | 18.08 | PHBBF |
| EPS (TTM) | $0.12 | $41.51 | REGN |
| Revenue Growth | 0.2% | 0.0% | PHBBF |
| Gross Margin | 34.7% | 44.6% | REGN |
Analyze PHBBF
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is PHBBF or REGN a better investment?
Comparing PHBBF and REGN: Pharmaron Beijing Co., Ltd. has a market cap of $3.55B while Regeneron Pharmaceuticals Inc has $79.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between PHBBF and REGN?
PHBBF (Pharmaron Beijing Co., Ltd.) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: PHBBF or REGN?
Based on P/E ratios, PHBBF trades at a lower multiple (16.1x vs 18.1x).
Which is growing faster: PHBBF or REGN?
PHBBF has higher revenue growth at 0.2% vs 0.0% for REGN.
Which company is more profitable: PHBBF or REGN?
Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 44.6% compared to 34.7% for PHBBF.
Which is the larger company: PHBBF or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.35B compared to $3.55B for PHBBF.
Should I buy PHBBF or REGN in 2026?
Both PHBBF and REGN have investment merit. PHBBF trades at $1.93 while REGN trades at $750.57. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between PHBBF and REGN stock?
Key differences: Market Cap ($3.55B vs $79.35B), P/E Ratio (16.1x vs 18.1x), Revenue Growth (0.2% vs 0.0%), Gross Margin (34.7% vs 44.6%).